Increased serum soluble OX40 in patients with systemic sclerosis

Kazuhiro Komura; Ayumi Yoshizaki; Masanari Kodera; Yohei Iwata; Fumihide Ogawa; Kazuhiro Shimizu; Takamasa Wayaku; Toru Yukami; Maki Murata; Minoru Hasegawa; Manabu Fujimoto; Kazuhiko Takehara; Shinichi Sato

doi:10.3899/jrheum.080120

Increased serum soluble OX40 in patients with systemic sclerosis

Kazuhiro Komura, Ayumi Yoshizaki, Masanari Kodera, Yohei Iwata, Fumihide Ogawa, Kazuhiro Shimizu, Takamasa Wayaku, Toru Yukami, Maki Murata, Minoru Hasegawa, Manabu Fujimoto, Kazuhiko Takehara, Shinichi Sato

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods. Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results. OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

Original language	English
Pages (from-to)	2359-2362
Number of pages	4
Journal	Journal of Rheumatology
Volume	35
Issue number	12
DOIs	https://doi.org/10.3899/jrheum.080120
Publication status	Published - 12-2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Rheumatology
Immunology and Allergy
Immunology

Access to Document

10.3899/jrheum.080120

Cite this

@article{8cf4b21459dd4e628f21668689a59e6b,

title = "Increased serum soluble OX40 in patients with systemic sclerosis",

abstract = "Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods. Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results. OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.",

author = "Kazuhiro Komura and Ayumi Yoshizaki and Masanari Kodera and Yohei Iwata and Fumihide Ogawa and Kazuhiro Shimizu and Takamasa Wayaku and Toru Yukami and Maki Murata and Minoru Hasegawa and Manabu Fujimoto and Kazuhiko Takehara and Shinichi Sato",

year = "2008",

month = dec,

doi = "10.3899/jrheum.080120",

language = "English",

volume = "35",

pages = "2359--2362",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology",

number = "12",

}

TY - JOUR

T1 - Increased serum soluble OX40 in patients with systemic sclerosis

AU - Komura, Kazuhiro

AU - Yoshizaki, Ayumi

AU - Kodera, Masanari

AU - Iwata, Yohei

AU - Ogawa, Fumihide

AU - Shimizu, Kazuhiro

AU - Wayaku, Takamasa

AU - Yukami, Toru

AU - Murata, Maki

AU - Hasegawa, Minoru

AU - Fujimoto, Manabu

AU - Takehara, Kazuhiko

AU - Sato, Shinichi

PY - 2008/12

Y1 - 2008/12

N2 - Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods. Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results. OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

AB - Objective. To determine levels of serum soluble OX40 (also termed CD134, a member of the tumor necrosis factor receptor superfamily) and their clinical associations in patients with systemic sclerosis (SSc). Methods. Serum soluble OX40 levels were examined by ELISA in 53 patients with SSc, 15 patients with systemic lupus erythematosus (SLE), and 32 healthy individuals. Results. OX40 levels were significantly elevated in SSc patients (125.7 ± 5.7 pg/ml) compared to patients with SLE (80.7 ± 1.7 pg/ml; p < 0.005) and controls (88.2 ± 3.0 pg/ml; p < 0.0001). Elevated OX40 levels were found to be associated with disease duration of less than 2 years (p < 0.05). Conclusion. Our results suggest that serum soluble OX40 levels correlate with the early-onset of SSc disease.

UR - http://www.scopus.com/inward/record.url?scp=57349168552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57349168552&partnerID=8YFLogxK

U2 - 10.3899/jrheum.080120

DO - 10.3899/jrheum.080120

M3 - Article

C2 - 18843780

AN - SCOPUS:57349168552

SN - 0315-162X

VL - 35

SP - 2359

EP - 2362

JO - Journal of Rheumatology

JF - Journal of Rheumatology

IS - 12

ER -

Increased serum soluble OX40 in patients with systemic sclerosis

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this